Benzoporphyrin-derivative photosensitizer for photodynamic therapy

Class

Benzoporphyrin-derivative photosensitizer for photodynamic therapy (verteporfin for injection; brand Visudyne)

Pathway

Preferentially taken up by proliferating neovascular endothelium via lipoprotein-receptor-mediated uptake; upon activation by non-thermal (689 nm) laser light in the presence of oxygen, generates reactive singlet oxygen/reactive oxygen radicals causing local endothelial damage and occlusion of choroidal neovascularization — a light-activated physicochemical mechanism, not a discrete protein-binding target

Notes

original target text: Benzoporphyrin-derivative photosensitizer for photodynamic therapy (verteporfin for injection; brand Visudyne)

This mechanism describes a photosensitizer, a light-activated compound used in photodynamic therapy rather than a conventional drug target such as a receptor or enzyme. Benzoporphyrin-derivative photosensitizers are lipophilic molecules that, after intravenous administration, become preferentially concentrated in rapidly proliferating tissue such as abnormal new blood vessels (neovascularization), because these vessels take up circulating lipoproteins at a higher rate than normal tissue and the photosensitizer travels bound to lipoprotein particles. On its own, the compound is biologically inert. Its activity is triggered by exposure to light of a specific, non-thermal wavelength delivered locally, typically by laser. In the presence of oxygen, this light exposure converts the photosensitizer into an excited state that generates reactive oxygen species, chemically aggressive molecules that damage cellular membranes and proteins. Because the photosensitizer has accumulated selectively in neovascular tissue, this photochemical damage is concentrated there, causing localized endothelial injury, clot formation, and closure of the abnormal vessels while relatively sparing surrounding normal tissue. This approach is broadly relevant to diseases driven by pathological blood vessel growth, particularly in the eye, where abnormal choroidal vessels can leak fluid and blood and threaten vision. The rationale for this light-and-drug combination is spatial control: therapeutic effect occurs only where both the compound and the activating light coincide.